Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas

There is a pressing need for more effective therapies to treat patients with T-cell lymphomas (TCLs), including first-line approaches that increase the response rate to cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP) chemotherapy. We characterized the mitochondrial apoptosis pathway...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Koch, Raphael, Christie, Amanda L., Crombie, Jennifer L., Palmer, Adam C., Plana, Deborah, Shigemori, Kay, Morrow, Sara N., Van Scoyk, Alexandria, Wu, Wenchao, Brem, Elizabeth A., Secrist, J. Paul, Drew, Lisa, Schuller, Alwin G., Cidado, Justin, Letai, Anthony, Weinstock, David M.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2019
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6367646/
https://ncbi.nlm.nih.gov/pubmed/30498064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-07-865527
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars